Improving Cardiorenal Outcomes Using SGLT2 Inhibitors in Multimorbid Patients with CKD

Improving Cardiorenal Outcomes Using SGLT2 Inhibitors in Multimorbid Patients with CKD is organized by National Kidney Foundation (NKF).

Available From: 7/27/2023
Available Until: 7/27/2024

Course Description: 
Individuals living with kidney disease are at increased risk of cardiovascular disease and worse cardiovascular outcomes. Current guidelines recommend the addition of SGLT2i to improve cardiorenal outcomes in these high risk individuals. This symposium will consist of scientific presentations by clinical experts who will provide up-to-date information about new developments in cardio- and renoprotective therapies using SGLT2i.

Learning Objectives:
• Summarize the epidemiology of CKD and T2D and describe key clinical outcomes in patients with multi-morbid patients with cardiorenal- metabolic conditions
• Review recent updates of major clinical practice guidelines with respect to the treatment of patients with CKD with diabetes or at high risk for cardiovascular outcomes
• Describe the mechanisms of action of SGLT2i and summarize the results of recent clinical trials examining kidney and cardiovascular outcomes in patients treated with SGLT2i.

Additional details will be posted as soon as information is available

1.5 AMA PRA Category 1 Credit™ | 1.5 Contact Hours | 1.5 MOC | 1.5 CPEUs | 1.5 CE Credits | 1.5 CECH | 1.5 CEP